Corrigendum to "Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology volume 31 (2020) 1476-1490]

Affiliations

• ¹ Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg; Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg, Germany.
• ² Department of Endocrinology, Reference Centre for Rare Adrenal Diseases, Reference Centre for Rare Adrenal Cancers, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Paris; Institut Cochin, Institut National de la Santé et de la Recherche Médicale U1016, Centre National de la Recherche Scientifique UMR8104, Université Paris Descartes, Sorbonne Paris Cité, Paris.
• ³ Department of Endocrine Oncology and Nuclear Medicine, Gustave Roussy, Villejuif, France.
• ⁴ Department of Medicine III and Institute of Clinical Chemistry and Laboratory Medicine, Technische Universität Dresden, Dresden, Germany.
• ⁵ Department of Medical Oncology, Centre Léon Bérard, University Claude Bernard Lyon I, Lyon, France.
• ⁶ Department of Internal Medicine Máxima Medisch Centrum, Eindhoven; Department of Internal Medicine, Division of General Internal Medicine, Maastricht University Medical Centre, Maastricht; Maastricht University, CAPHRI School for Public Health and Primary Care, Ageing and Long-Term Care, Maastricht.
• ⁷ Department of Pathology, University Medical Center Utrecht, Utrecht; Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
• ⁸ Division of Urology, San Luigi Hospital e Orbassano, Turin; Department of Oncology, University of Turin, Turin.
• ⁹ Internal Medicine, Department of Clinical and Biological Sciences, San Luigi Hospital, University of Turin, Turin.
• ¹⁰ Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, ASST-Spedali Civili, Brescia, Italy.